PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
Rahul Aggarwal,Glenn Heller,David W. Hillman,Han Xiao,Joel Picus,Mary-Ellen Taplin,Tanya Dorff,Leonard Appleman,Douglas Weckstein,Akash Patnaik,Alan Bryce,Daniel Shevrin,James Mohler,Daniel Anderson,Arpit Rao,Scott Tagawa,Alan Tan,Susan Halabi,Katharine Dooley,Patrick O'Brien,Ronald Chen,Charles J. Ryan,Scott E. Eggener,Michael J. Morris,Rahul Aggarwal,Daniel Shevrin,Scott Tagawa,Charles Kim,Mary-Ellen Taplin,Young Whang,Shaker Dakhil,Raymond Smith,Benjamin Gartrell,Seth Fagbemi,Rex Mowat,Charles Farber,Neda Hashemi,Michael Humeniuk,Charles Ryan,John Ellerton,Mark Olsen,Jennifer Wang,Tanya Dorff,Sheila Karina Pascual,Douglas Weckstein,Douglas Weckstein,Alan Bryce,James Mohler,James Michael Randall,Han Xiao,Akash Patnaik,David King,Joel Picus,Deepak Kilari,Paul Monk,Rhonda Bitting,Leonard Appleman,Jose Eugenio Najera,Kendrith Rowland,Ralph Hauke,Nasfat Shehadeh,Brendan Curti,Gopal Gupta,Alan Tan,Timothy Collins,Tomasz Beer,David Tate,Bryant Sheh,Alina Basnet,James Conway,Howard Gross,Michael Goodman
DOI: https://doi.org/10.1200/jco.23.01157
IF: 45.3
2024-01-23
Journal of Clinical Oncology
Abstract:PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen receptor antagonist, and abiraterone acetate plus prednisone (AAP) prolong survival in the metastatic setting. We evaluated whether intensification of androgen-deprivation therapy (ADT) improves outcomes in BRPC. PATIENTS AND METHODS PRESTO is a randomized phase III, open-label trial in patients with BRPC and PSA doubling time ≤9 months (ClinicalTrials.gov identifier: NCT03009981 ). Patients were randomly assigned 1:1:1 to receive a finite 52-week treatment course with ADT control, ADT + apalutamide, or ADT + apalutamide + AAP. The primary end point was PSA progression-free survival (PSA-PFS), defined as serum PSA >0.2 ng/mL after treatment completion. RESULTS Five hundred three patients were enrolled. The median PSA was 1.8 ng/mL (IQR, 1.0-3.6). At the first planned interim analysis, both experimental arms significantly prolonged PSA-PFS compared with the control arm (median, 24.9 months for ADT + apalutamide v 20.3 months for ADT; hazard ratio [HR], 0.52 [95% CI, 0.35 to 0.77]; P = .00047; median, 26.0 months for ADT + apalutamide + AAP v 20.0 months for ADT; HR, 0.48 [95% CI, 0.32 to 0.71]; P = .00008). Median time to testosterone recovery did not differ across treatment arms. The most common grade ≥3 adverse event was hypertension (7.5%, 7.4%, and 18% in ADT, ADT + apalutamide, and ADT + apalutamide + AAP arms, respectively). CONCLUSION Intensified AR blockade for a finite duration prolongs PSA-PFS with a manageable safety profile, without adversely affecting time to testosterone recovery. The addition of apalutamide to ADT should be considered in patients with high-risk BRPC.
oncology